Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are incurable B-cell malignancies usually responsive to initial immunochemotherapy, but virtually all patients experience relapse. Salvage therapy choices for relapsed/refractory disease are often limited by resultant cytopenias and acquired drug resistance. The current priority in these B-cell malignancies, therefore, is to develop agents with novel mechanisms of action that are selective for tumor cells, overcome shared patterns of acquired drug resistance and exhibit limited toxicities.
Styrylbenzylsulfones are a new family of non-ATP-competitive anticancer agents that induce apoptosis in a variety of tumor cell lines, including those resistant to many chemotherapy agents. 1, 2 As a class, styrylbenzylsulfones inhibit cell cycle progression and induce mitotic arrest of tumor cells with less toxicity to normal human cells. 3, 4 ON 01910.Na (rigosertib) is a styryl sulfonyl compound that demonstrated inhibition of phosphatidylinositol-3-kinase (PI3K), preferentially targeting the PI3Ka and PI3Kb isoforms, and triggered apoptosis via the release of cytochrome c from mitochondria in MCL cell lines. 3 Rigosertib's mechanism of action was initially considered to include inhibition of polo-like 1 kinase, 4 but evidence for direct inhibition was not confirmed in subsequent studies 5 and its antimitotic activity may rely on the phosphorylation of mitosis coordinator RanGAP1 SUMO1. 6 First-in-man studies of rigosertib in solid tumors demonstrated excellent tolerability with limited hematologic toxicity. 7 Rigosertib has also demonstrated preclinical and early clinical activities in myelodysplastic syndromes (MDS), 8, 9 and it is currently being tested in a randomized phase III trial in patients with relapsed/refractory MDS (NCT01241500).
We have previously reported that rigosertib induces rapid apoptosis in CLL cells with the relative sparing of normal B-cells and T-cells. 10 We demonstrated that the in vitro activity of rigosertib involved a dual mechanism of inhibition of PI3K pathway signaling coupled with the induction of an oxidative stress response. Importantly, activity of rigosertib was equally observed against Accepted article preview online 14 March 2013; advance online publication, 12 April 2013 Letters to the Editor CLL cells with adverse prognostic features such as unmutated immunoglobulin heavy-chain variable regions and the loss of TP53. These preclinical data prompted our exploration of rigosertib in lymphoid malignancies. In this letter, we report the safety and clinical toxicity profile of rigosertib in patients with relapsed and refractory CLL, MCL and related B-cell lymphoid malignancies.
Adult patients aged X18 years with CLL, MCL, hairy cell leukemia (HCL) and multiple myeloma (MM) refractory or relapsed after X1 line of therapy were eligible. Patients had measurable disease and were ineligible for, or opted not to participate in alternative treatment options such as allogeneic transplantation. Exclusion criteria included systemic therapy (steroids-permitted) within 4 weeks of enrollment, Eastern Cooperative Oncology Group performance of X3, human immunodeficiency virus infection on antiretroviral therapy, glomerular filtration rate o40 ml/min, serum sodium o134 meq/l and the presence of active ascitic or pleural fluid (the latter exclusion criteria were based on preliminary reports of hyponatremia in patients with solid tumors treated with rigosertib). Patients with pre-existing cytopenias were eligible if their baseline absolute neutrophil count was X500 cells/ml and if their platelet count could be maintained above 10, 000 m/l by transfusion. There was no limit on previous numbers of regimens, and patients who had previously been treated with autologous or allogenetic stem cell transplantation were eligible. All research was approved by the Institutional Review Board of the National, Heart, Lung, and Blood Institute, and the study was conducted in accordance with the Declaration of Helsinki. Treatment responses were determined by the investigator using the updated International Workshop on Chronic Lymphocytic Leukemia response criteria for CLL, 11 the International Myeloma Working Group response criteria for MM 12 and the revised Cheson 13 response criteria for MCL. For HCL, complete response required absence of HCL cells in blood and bone marrow, no hepatosplenomegaly, and resolution of blood counts to neutrophils X1500/ml, platelets X100 000/ml and hemoglobin X11 g/dl in women and X12 g/dl in men; partial remission required X50% reduction in abnormal blood lymphocyte count, X50% reduction of lymphadenopathy, X50% reduction in abnormal hepatosplenomegaly and achievement of X50% improvement over baseline in normal blood counts; progressive disease was defined as X25% increase in adenopathy or appearance of new lymphadenopathy, X25% increase in liver or spleen measured below the costal margin, X25% decrease in normal blood counts or a X25% increase in circulating abnormal lymphocytes; stable disease was defined as the lack of complete response, partial remission or progressive disease.
Rigosertib was administered intravenously via an ambulatory infusion pump every 14 days across five cohorts in escalating doses. A standard phase 1 dose-escalation (3 þ 3) design was used. The first three cohorts received rigosertib according to body-surface area calculations over 48 h in escalating doses of 1500 mg/m 2 /day Â 2 days, 1800 mg/m 2 /day Â 2 days and 2100 mg/m 2 /day Â 2 days. The protocol was amended to flat dosing for cohorts 4 and 5 based on information that infusions over 72 h were more effective in MDS (unpublished data). Thus, cohorts 4 and 5 received flat dosing of rigosertib at 1800 mg/ day Â 3 days (the dose currently being studied in the phase III study in patients with MDS) and 2100 mg/day Â 3 days (Table 1) . Dose-limiting toxicity was defined as any G3 or higher nonhematologic toxicity that was not readily reversible and G3 or higher hematologic toxicities that did not resolve in 14 days occurring in the first two cycles of therapy. The primary end point of the study was to determine the toxicity profile (including the maximum tolerated dose and recommended phase 2 dose) of rigosertib after two cycles. A dose escalation beyond cohort 5 was not considered due to previous reports of dose-limiting toxicities in patients with acute myeloid leukemia or MDS treated at higher doses or with extended infusion duration (unpublished data). All patients were allowed to continue past the primary end point to day 56 (four cycles infused) to determine early clinical activity of rigosertib.
A total of 16 patients with relapsed CLL (10), MCL (2), MM (2) and HCL (2) were enrolled (Table 1 ). Median age of the patients was 61 years (range 52-65), and 10 of the 16 patients (63%) were of male gender. Over 30% of patients had pre-existing absolute neutrophil counts o1000 cells/ml, and the median number of prior regimens was 4 (range 2-9). Overall, toxicities were minimal and almost exclusively pG2 ( Table 2 ). The most common reported toxicities include musculoskeletal pain, nausea, constipation and diarrhea. Two cases of venous thrombosis associated with peripherally inserted central catheters were observed. Non-hematologic grade 3/4 drug-related adverse events included one case of syncope that did not recur upon subsequent dosing, and one case of elevated alanine aminotransferase that resolved without Letters to the Editor intervention. There was one cardiac death in a patient with preexisting heart disease that was classified as unrelated to study drug. Grade 3/4 hematologic toxicity occurred exclusively in patients with pre-existing cytopenias. One case of neutropenia occurred in a patient in cohort 3 with relapsed MM who had progressive bone marrow infiltration and resulted in discontinuation of protocol therapy. The other six cases of XG3 neutropenia occurred in two patients in cohort 5 both of whom had pre-existing neutropenia of G2 or higher. No dose-limiting toxicities were recorded and no patient discontinued study drug due to toxicity. Fourteen of the sixteen patients were evaluable for secondary end points including objective response or signs of early biologic activity such as reduction in tumor burden or tumor markers (Table 1) . Two patients were considered not evaluable for response: one patient with MM was unable to continue after only one cycle of therapy due to neutropenia, and the other patient with MM did not continue past cycle 2 due to rising light chains that did not meet criteria for progressive disease. No cases of early clinical activity were noted and no patient continued past four cycles of therapy. A total of 7/14 patients (50%) had stable disease and 7/14 (50%) had progressive disease.
We conclude that escalating doses of the multikinase inhibitor rigosertib are well-tolerated in patients with relapsed/refractory B-cell malignancies, and associated with a relative lack of hematologic toxicity. Our schedule tested doses higher than that currently in phase III testing in MDS patients and was associated with minimal toxicity. Heavily pre-treated patients with pre-existing cytopenias tolerated rigosertib without an increased risk of infection or significant worsening of blood counts. Despite the encouraging preclinical activity, no significant clinical activity was observed with rigosertib as a single agent in these B-cell malignancies. Further development of rigosertib for lymphoid malignancies will require either combination therapy 14 or alternative dosing schedules.
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Abbreviation: ALT, alanine aminotransferase. Two events of G4 neutropenia were observed in cohort 5 in patient with pre-existing G3 neutropenia. Four events of G3 neutropenia were observed in cohort 5 in patient with pre-existing G2 neutropenia. All events were felt possibly due to drug and possibly due to disease.
Letters to the Editor Applicability of a reproducible flow cytometry scoring system in the diagnosis of refractory cytopenia of childhood Myelodysplastic syndrome (MDS) in childhood is rare and has an estimated incidence per year of about 0.8-1.8 per million children aged 0 to 14 years. [1] [2] [3] The most common subtype of childhood MDS, accounting for about half of all cases, is refractory cytopenia of childhood (RCC), defined as myelodysplasia without an increased blast count. 4, 5 Karyotype is normal in the majority of patients with RCC, and, in contrast to adults with MDS-refractory anemia, about 80% of children have a hypocellular bone marrow (BM). 6 Although morphologic criteria for diagnosing RCC are strictly defined, 5 differentiating RCC from the immune-mediated BM failure syndrome aplastic anemia can be challenging. Similarly, difficulties can be encountered in differentiating, based on morphologic criteria, non-clonal cytopenias from low-grade MDS in adults, especially in cases without cytogenetic aberrations or specific morphologic abnormalities such as ring sideroblasts. Flow cytometric immunophenotyping has been suggested as valuable addition to morphology in the diagnosis of MDS. 7 Recently, Ogata and others described a simple, reproducible flow cytometric scoring system as diagnostic tool in adult low-grade MDS with a sensitivity of 70% and a specificity of 93%. 8, 9 The diagnostic utility of this scoring system in RCC is unknown. Here we describe its applicability in childhood MDS, with emphasis on RCC, using pediatric advanced MDS patients, low-grade adult MDS patients, healthy individuals and cytopenic non-MDS patients as controls.
BM samples obtained from 82 primary RCC patients (median age: 10.5 years, range: 1.3-17.9), not previously treated with immunosuppressive therapy, were available for analysis by flow cytometry. Patients were diagnosed from June 2005-December 2011 and enrolled in the prospective, multi-center studies EWOG-MDS 2006 and EWOG-MDS RC06 (ClinicalTrial.gov: NCT00662090 and NCT00499070). BM was hypocellular in 66 patients (81%), and normo-or hypercellular in 16 of 82 patients (20%). Cytogenetic analysis was normal in 62 patients (76%), monosomy 7 was present in 5 patients (6%), and other aberrations in 5 patients (6%); in 10 of 82 patients (12%) no result was obtained due to insufficient metaphases. Institutional review boards of participating institutions approved the studies and parents or legal guardians of patients provided written informed consent for study participation. RCC was diagnosed according to WHO criteria 5 and confirmed by central review of BM morphology and histology. 10 BM samples were collected in heparinized tubes, sent to the Erasmus MC, and generally analyzed within 24 h from collection.
A minimum of 500 ml BM was lysed with NH 4 Cl, resuspended in 350 ml phosphate-buffered saline/bovine serum albumin or to a maximum concentration of 20 Â 10 6 cells/ml, and 50 ml aliquots were stained for 15 min at room temperature with CD7-FITC (3A1/1, 7F3, Sanquin, Amsterdam, the Netherlands), CD56-PE (C5.9, DAKO, Glostrup, Denmark), CD45-PerCP (2D1, BD Biosciences, Erembodegem, Belgium), CD19-PE-Cy7 (SJ25C1, BD), CD5-APC (L17F12, BD) and CD34ACP-Cy7 (8G12, BD) in tube 1, and CD3-FITC (SK7, BD), CD16-PE (B73.1, BD) and CD56-PE (C5.9 Zebra/ DAKO), CD45-PerCP (2D1, BD), CD10-PE-Cy7 (HI10a, BD), CD19-APC (SJ25C1, BD), and CD20-APC-Cy7 (L27, BD) or APC-H7 (L27, BD) in tube 2. Cells were acquired on a FACSCanto II flow cytometer (BD Biosciences). After exclusion of debris and dead cells based on scatter and CD45 expression, at least 100 000 cells were analyzed in 61 of 82 RCC patients (75%). In the remaining 21 patients, a median of 54 323 cells could be analyzed (range, 4 359-98 482). Flow cytometric data were analyzed with Infinicyt software (Cytognos, Salamanca, Spain) according to the published strategy. 9 Briefly, in tube 1, lymphocytes were gated within all nucleated cells in a CD45 and forward scatter (FSC) versus side scatter (SSC) plot, and blast cells were gated within CD45 versus CD34 and FSC versus SSC plots. Within this population, myeloid blast cells were identified as SSC high cells in a CD45 versus SSC plot (parameter 1), and B-cell progenitors were identified as SSC low cells (parameter 2). Next, the lymphocyte versus myeloid blast cell CD45 mean fluorescence intensity (MFI) ratio was calculated (parameter 3). In tube 2, lymphocytes and granulocytes were gated in CD45 and FSC versus SSC plots, and SSC peak channel values of granulocytes versus lymphocytes were calculated (parameter 4). Samples were evaluated based on the published cutoffs (determined in 281 adults with low-grade MDS and 257 non-clonal cytopenic adult controls): CD34 þ myeloid blast cells (parameter 1) X2%, CD34 þ B-cell progenitors within CD34 þ blast cells (parameter 2) p5%, lymphocyte/myeloid blast cell CD45 MFI ratio (parameter 3) p4 or X7.5, granulocyte/lymphocyte SSC peak channel ratio (parameter 4) p6. 9 Patients scored 1 point for each fulfilled criteria; patients scoring X2 points were considered likely to have MDS. 9 To validate the scoring system in our laboratory, 8 low-grade adult MDS patients, 28 cytopenic non-clonal adult controls, and 9 healthy adult controls were evaluated (Figure 1 ). Seven of 8 MDS patients (87.5%), 2 of 28 cytopenic controls (7.1%) and 0 of 9 healthy controls scored positive (X2 points) (Table 1) , which is comparable to the previously published sensitivity of 70% and specificity of 93%.
Subsequently, 82 RCC patients were analyzed (Figure 1 ). In these patients, the percentage of myeloid blast cells was generally Accepted article preview online 15 March 2013; advance online publication, 12 April 2013
